
	Where results make sense

Topic: Boston Scientific

Related Topics

CIGNA

Peter Nicholas

ConocoPhillips

Goldman Sachs Group Incorporated

Fortune 500

Kroger

Bank of America

	Boston Scientific, Medinol settle row - The Boston Globe
		Boston Scientific Corp. agreed last night to pay $750 million to settle claims that it broke its contract and stole technology from an Israeli company in the late 1990s, according to a company statement issued last night.
		Boston Scientific also gave up a 20 percent ownership share in Medinol that it had taken as part of the original contract, and the companies agreed that future disputes or royalty demands would be resolved through arbitration.
		Boston Scientific almost immediately countersued, claiming Medinol's owners were abusive and obstructionist, and had cost Boston Scientific hundreds of millions of dollars in business by delaying and threatening to stop stent shipments.
	www.boston.com /business/technology/biotechnology/articles/2005/09/22/boston_scientific_medinol_settle_row (887 words)

	Boston Scientific Stent Recall Lawsuit - Lawyers Taking Cases Nationwide.
		In August of 2004 Boston Scientific and the FDA issued a recall of the "Express" and "Taxus" stents.
		Boston Scientific, one of the nation's largest medical-device manufacturers with more than $5.6 billion in annual sales, is the leading maker of stents, whose implantation is the most common form of cardiac surgery in the U.S. Analysts expect 1.4 million stent-implantation surgeries to be performed this year.
		Boston Scientific said it identified and fixed the manufacturing flaw that led to the defect and that its goal was to lower "complaint rates for no deflates" to less than one in 100,000.
	www.ennislaw.com /boston_scientific_stent_recalll.html (1822 words)

	Boston Scientific: buyer's remorse? - Boston.com
		BOSTON --Johnson and Johnson is suing Boston Scientific Corp. over its lost bidding war to buy medical-devices maker Guidant Corp. But eight months after trumping its rival to acquire Guidant's defibrillator and pacemaker business, Boston Scientific is hardly looking like the victor.
		Boston Scientific expects long-term growth prospects from pairing its strength in coronary stents with Guidant's expertise in defibrillators and pacemakers.
		Boston Scientific sparked a bidding war in December that derailed a standing agreement JandJ struck to purchase Indianapolis-based Guidant.
	www.boston.com /business/healthcare/articles/2006/09/27/boston_scientific_buyers_remorse?mode=PF (853 words)

	Boston Scientific (Site not responding. Last check: 2007-10-26)
		Boston Scientific Endoscopy is the only manufacturer of a combination therapy device, injection and thermal, for the treatment of actual or potential bleeding sites in the GI tract.
		Boston Scientific is committed to advancing the practice of less-invasive medicine for the digestive and airway systems.
		Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 28,000 employees and revenue of $6.3 billion in 2005.
	www.bostonscientific-international.com /common_templates/standardOverview.jsp?task=tskDivisionOverview.jsp§ionId=2&relId=1,2,6 (431 words)

	SignOnSanDiego.com > News > Business -- Boston Scientific prepared to accept legal risks, higher debt with ...
		BOSTON – If Boston Scientific Corp. prevails in a bidding war for rival medical device maker Guidant Corp., the $25 billion deal would quadruple its debt load, hurt its near-term earnings and add to the company's recent legal and regulatory troubles.
		Boston Scientific is eager to jump into the $10 billion global market for pacemakers and defibrillators as JandJ and others work to topple the Natick, Mass.-based company as the leading maker of drug-coated heart stents.
		Boston Scientific says it's prepared to inherit the legal woes at Guidant, which acknowledged in a regulatory filing last month that it faced nearly four dozen product liability class action lawsuits, 50 individual lawsuits, as many as a dozen securities fraud lawsuits and regulatory investigations.
	www.signonsandiego.com /news/business/20051206-1354-guidant-biddingwar.html (933 words)

	Boston Scientific Announces Nationwide Recall of 51 Mach 1 Guide Catheters
		An obstruction of a small blood vessel by an embolism may not cause tissue damage; however, an obstruction of a major blood vessel or multiple small blood vessels could result in serious complications such as stroke, heart attack or kidney problems.
		To date, no product complaints have been reported to Boston Scientific related to this issue, and there have been no reported injuries.
		Boston Scientific is notifying affected hospitals through detailed recall notification letters requesting that use of the product affected by this recall should cease immediately.
	www.fda.gov /oc/po/firmrecalls/bostonsci12_06.html (384 words)

	Guidant Spurns Boston Scientific - Health - RedOrbit
		Although Boston Scientific is widely seen as aggressive and tenacious competitor, Wald said, the additional cash could make it hard for the Natick device maker to keep competing against one of America's largest corporations.
		Boston Scientific first jumped into the fray in December by making a surprise $25 billion offer for the Indianapolis company, trying to lure it away from a $22 billion deal it had already signed with Johnson & Johnson.
		Wald estimated that Boston Scientific could bid as high as $76 a share, or $26 billion, without hurting its bottom line or its bond rating, although others say that as the price climbs the company will be hampered by the need to assume more debt.
	www.redorbit.com /news/health/357884/guidant_spurns_boston_scientific/index.html?source=r_health (810 words)

	Boston Scientific Corporation information and related industry information from Hoover's United Kingdom (UK)
		Boston Scientific operates under the threat of minimal invasion.
		Boston Scientific markets in some 70 countries worldwide, primarily through its own direct sales staff.
		After a long struggle with rival Johnson and Johnson to acquire Guidant, Boston Scientific emerged the winner; the deal is valued at $27 billion and was completed in 2006.
	www.hoovers.com /boston-scientific-corporation/--ID__15683--/freeuk-co-factsheet.xhtml (551 words)

	Guidant Suits Mount at Boston Scientific (Site not responding. Last check: 2007-10-26)
		Boston Scientific faces more than 1,175 individual and class-action lawsuits over recalls and safety warnings issued in 2005 and 2006 involving Guidant's implantable defibrillators and pacemakers, the company said in an annual filing made after markets closed Thursday.
		Although the lawsuits are still pending in various courts, Boston Scientific said it had set aside $485 million "for legal matters that are probable and estimable" as of Dec. 31, primarily related to Guidant.
		Boston Scientific has said the legal and other risks are offset by the increased sales it expects from acquiring Guidant's defibrillators and other medical devices.
	www.springfieldnewssun.com /money/content/shared-gen/ap/Finance_General/Boston_Scientific_Lawsuits.html (743 words)

	Boston Scientific's Murky Prognosis - MoneyNews Story - WCVB Boston
		Boston Scientific reported fourth quarter net income of $277 million, or 19 cents per share, which included net special credits [after-tax] of $127 million [9 cents per share], down from $334 million, or 40 cents per share, in the year-earlier quarter.
		Boston Scientific has come under fire recently because it makes stents, which are metal objects used to keep arteries open even after illness has made them collapse.
		Boston Scientific already said in January that it plans to cut 500 to 600 employees in the first quarter of 2007.
	www.thebostonchannel.com /money/10910822/detail.html (722 words)

	Boston Scientific Buys 'Divorce' Cover - Tax - CFO.com (Site not responding. Last check: 2007-10-26)
		On the surface, the public bidding war between Boston Scientific and Johnson and Johnson to buy Guidant Inc., was a fairly routine merger story: two industry giants with multi-line businesses slugging it out to win the right to acquire a coveted target company.
		Boston Scientific emerged as the official victor last week when Guidant's board approved the $27 billion offer at $80 per share.
		Consider that if Boston Scientific's step-up in Guidant stock is about $24-billion (the $27 billion purchase price minus the $3 billion basis in Guidant's stock) the company could save nearly $10 billion in taxes on a future sale of Guidant.
	www.cfo.com /article.cfm/5464056?f=home_featured (672 words)

	Despite Sales Uptick, Boston Scientific Will Cut Jobs - New York Times
		BOSTON, Jan. 8 (AP) — Boston Scientific said on Monday that it would eliminate 500 to 600 jobs from its cardiac rhythm division, with most of the cuts coming at a Minnesota-based office the company acquired in its $27 billion acquisition of Guidant Corporation last spring.
		Boston Scientific has sought to restore confidence in Guidant’s defibrillator and pacemaker business after a string of recalls and safety warnings starting in 2005 resulting from device malfunctions.
		Boston Scientific, which is based in Natick, Mass., bought Guidant and its lines of defibrillators and pacemakers to help offset increasing competitive challenges for the Taxus stent.
	www.nytimes.com /2007/01/09/business/09BostonSci.html?ex=1325998800&en=181401ebf56d532b&ei=5088&partner=rssnyt&emc=rss (597 words)

	USATODAY.com - Boston Scientific wins over Guidant (Site not responding. Last check: 2007-10-26)
		After favoring JandJ's earlier offers, Guidant's board reversed course and said a revised $27.2 billion bid by Boston Scientific (BSX) Tuesday is superior to JandJ's latest $24.2 billion offer.
		Dec. 5: Boston Scientific announces unsolicited offer of about $24.6 billion for Guidant, begins four weeks of due diligence talks with Guidant before offer is formalized Jan. 8.
		Boston Scientific and JandJ are wrestling for position in the growing, multibillion-dollar market for heart devices.
	www.usatoday.com /money/industries/health/2006-01-17-guidan-boston-scientific_x.htm (653 words)

	S&P cuts Boston Scientific on financial weakness \| Reuters (Site not responding. Last check: 2007-10-26)
		Boston Scientific benefits from a broad portfolio of market-leading medical devices and strong cash flows.
		SandP cut Boston Scientific's rating by one notch to "BBB," its second-lowest investment grade ranking, from "BBB-plus." The outlook is negative, indicating an additional cut is likely over the next one to two years.
		Boston Scientific's 5.45 percent bond due 2014 traded at 1.52 percentage points over Treasuries on Monday, its last recorded trade, according to MarketAxess.
	www.reuters.com /article/idUSN0529818620061205 (390 words)

	Boston Scientific Gets Guidant, For $27B After J & J Fails To Raise Bid For Heart Device Company - CBS News
		Last week, Guidant's board said Boston Scientific's $80-per-share offer was favorable to a lower, $71-per-share offer from J&J. A five-day period for J&J to sweeten its $24.2 billion bid expired at midnight.
		Boston Scientific officials said they expect the deal to close in the first quarter.
		Boston Scientific plans to sell Guidant's line of drug-coated stents to Abbott Laboratories for $6.4 billion in cash.
	www.cbsnews.com /stories/2006/01/25/business/main1236024.shtml (629 words)

	FTC Requires Asset Divestitures Before Allowing Boston Scientific’s $27 Billion Acquisition of Guidant Corporation (Site not responding. Last check: 2007-10-26)
		First, it requires Boston Scientific to divest Guidant’s vascular business, which includes, among other things, its DES development program (including the RX delivery system patents) and its PTCA balloon catheter and coronary guidewire products, to an up-front buyer approved by the FTC.
		Boston Scientific also will divest its equity investment in Cameron within eighteen months if it does not acquire Cameron prior to the expiration of its option to do so.
		Also pursuant to the order, Boston Scientific will notify the FTC prior to any attempt to exercise its option to acquire Cameron.
	www.ftc.gov /opa/2006/04/bostonscigui.htm (1281 words)

	Boston Scientific Reports a Profit - New York Times
		BOSTON, Oct. 18 (AP) — The Boston Scientific Corporation, the medical device maker, said on Wednesday that it had a $76 million profit in the third quarter, a result that narrowly beat Wall Street estimates.
		Boston Scientific said net income for the quarter was 5 cents a share, in contrast to a loss of $269 million, or 33 cents a share, in the period a year ago, when it recorded a $598 million expense for a legal settlement.
		Sales of Boston Scientific’s top-selling product, the Taxus drug-coated stent, fell 5 percent, to $572 million, from $601 million in the quarter a year ago.
	www.nytimes.com /2006/10/19/business/19device.html?ex=1318910400&en=8817e4943e74e02f&ei=5088&partner=rssnyt&emc=rss (185 words)

	FDA sends warning letter to Boston Scientific - U.S. Business - MSNBC.com
		Boston Scientific and the FDA separately disclosed the warning letter Thursday, after markets closed for the day.
		Jim Tobin, Boston Scientific's president and chief executive, said in a news release, "we have clearly not done enough to resolve the issues raised by the FDA last year." But he said the company was on track to resolve outstanding issues promptly.
		In the summer of 2004, Boston Scientific recalled nearly 100,000 units of the Taxus stent and another model not coated with drugs because of a manufacturing defect that the company has said it has fixed.
	www.msnbc.msn.com /id/11047582 (433 words)

	Latest Boston Scientific News – Examiner.com
		Boston Scientific may spin off stake in endosurgery group
		1 day ago - Boston Scientific Corp. said Monday it's considering selling a minority stake in its endosurgery group, a move that could draw attention to the unit's growth and help pay off debt while the medical device maker's stock struggles to recover from a $27 billion acquisition.
		Boston Scientific CEO awarded compensation valued at $23M in 2006
	www.examiner.com /Topic-Boston_Scientific.html (545 words)

	BostonWorks Hiring Hub: Boston Scientific Case Study
		Boston Scientific is the world's largest medical device manufacturer dedicated to interventional medicine.
		Boston Scientific has continued to hire through a challenging economy and has chosen BostonWorks to help build its recruitment brand.
		On top of that, job fairs have provided us with good brand exposure, positioning Boston Scientific as a company that is doing well and hiring.
	bostonworks.boston.com /mediakit/case_studies/boston_scientific (332 words)

	Boston Scientific seeks to change company bylaws \| News \| Mergers/Acquisitions \| Reuters (Site not responding. Last check: 2007-10-26)
		BOSTON (Reuters) - Boston Scientific Corp. (BSX.N: Quote, Profile, Research) said on Thursday that it will adopt a majority voting standard for the election of directors in uncontested elections.
		The medical device maker also said it is recommending that shareholders approve an amendment to the company's bylaws that would declassify the company's board of directors and cause each to be elected annually for a one-year term.
		Boston Scientific is recommending shareholders approve its proposals at the company's annual meeting on May 8.
	www.reuters.com /article/mergersNews/idUSWEN523720070308 (275 words)

	Boston Scientific
		Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 16,000 employees and revenue of $5.6 billion in 2004.
		This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare.
		Boston Scientific's history began in the late 1960s, when co-founder John Abele acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to traditional surgery.
	company.monster.ie /bostonie (274 words)

	Boston Scientific Offers $25B for Guidant
		The gate of Boston Scientific Corp. is seen Aug. 23, 2005, in a Natick, Mass.
		Boston Scientific Corp. has offered about $25 billion for Guidant Corp., topping by more than $3 billion what Johnson & Johnson agreed to pay for the medical device manufacturer last month.
		Boston Scientific, whose products include the top-selling cardiac stent Taxus, offered Guidant a combination of cash and stock worth about $72 per Guidant share _ a 16 percent premium over Friday's close.
	www.washingtonpost.com /wp-dyn/content/article/2005/12/05/AR2005120500402.html (517 words)

	Boston Scientific Corporation
		Cette amÃ©lioration est la premiÃ¨re Ã©tape de l'Ã©volution internationale de Boston Scientific en ligne : le site vous offre toutes les informations internationales dont vous avez besoin.
		Boston Scientific is helping to improve K-12 science literacy in San Diego,CA....
		Boston Scientific forms an alliance with B&K Medical to develop and market a catheter-based intraluminal ultrasound imaging system
	www.bostonscientific.fr (177 words)

Try your search on: Qwika (all wikis)